Key facts
- It has raised $3.0M; the latest was Seed Round ($3.0M) in Jan 2026.
- Notable investors include The FSE Group.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Green Park Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Green Park Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Green Park Pharma
Developer of pharmaceutical formulations intended to address patient challenges with solid oral dosage forms. The company offers reformulated medicines in patient-friendly formats, improving medication adherence and quality of life for individuals who struggle with traditional pill swallowing, enabling healthcare providers to offer compliance and increasing treatment accessibility in global markets.
- Sector
- Healthcare
- HQ
- Newquay, United Kingdom
- Founded
- 2022
- Employees
- 7
- Website
- greenparkpharma.com/
- Ownership
- Privately Held (backing)
Green Park Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Green Park Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Green Park Pharma in its N-PORT filings yet. We sweep new filings monthly.